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Description of the Physiological Model  Abstract: The complex and dynamic 
pathophysiology of sepsis make the design of the best 
approach to therapy one of the most challenging 
tasks in ICU. This is due to the large amount of 
clinical information which need to be effectively and 
safely put into practice in the management of 
critically ill patients in general and septic shock 
patients in particular. The provision of a computer 
guided treatment strategy based on a comprehensive 
physiological model is an attractive approach in the 
management of septic patients. This paper presents 
preliminary studies on the non-linear modelling of 
the cardiovascular system interaction with the most 
routinely used vaso-active drug in ICU. A case study 
with dobutamine is explored to illustrate  the 
interaction between the cardiovascular and 
pharmacological models. 
 
     The overall model structure is shown in Figure 1.  
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Figure 1: Structure of the physiological model 
 
     The cardiovascular system (CVS) model consists of 
fourteen compartments describing the systemic, 
pulmonary, coronary and cerebral circulations. Figure 2 
shows the model layout.   
 
Introduction 
  
     Sepsis is the systemic response to bacterial infections 
and is the most common cause of mortality in the 
intensive care units. Septic shock is associated with 
three major pathophysiological effects on the 
cardiovascular system : vasodilation, hypoperfusion and 
myocardial depression [1]. The first principles of 
hemodynamic support of patient with septic shock is to 
provide adequate fluid resuscitation, vasopressor 
therapy and inotropic therapy. After adequate fluid 
resuscitation, most septic patients become 
hyperdynamic. Despite this, myocardial contractility 
may still be decreased especially in patients with   pre-
existing cardiac dysfunction. Inotropic agents are useful 
if the patient demonstrates a low cardiac output state.    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
     One such inotropic agent which is frequently used in 
intensive care units is dobutamine. Dobutamine’s 
primary effect is to increase myocardial contractility by 
directly stimulating β1-receptors in the heart. This is 
accompanied by a minimal chronotropic and vascular 
effecs. If used in the presence of low blood pressure, the 
addition of a vasopressor such as noradrenaline is 
necessary to restore an adequate systemic vascular 
resistance.  
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     The physiological model used in this study combines 
a pulsatile model of the cardiovascular mechanics with 
pharmacological model which describes drug transport 
throughout the various parts of the body. 
Figure 2: The cardiovascular system model structure 
 
Each compartment consists of a compliant element 
(C) and a resistance (R) as shown in Figure 3.  
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Where V denotes the total blood volume available in the 
relevant compartment (stressed and unstressed). 
     The drug effect model relates the concentration of 
drug in the different compartments to the changes in the 
corresponding parameters values. An exponential 
function has been employed to describe this 
relationship. The parameters of the exponential function 
are optimised using the Levenberg-Marquardt algorithm 
based on the available effect data given for dobutamine. 
Figure 3: Electric analog model of a compartment  
 
Where P=pressure, Q=flow and V=volume. V0 denotes 
the unstressed volume of the relevant compartment. 
     Flow into the circulation is maintained by a pulsatile 
cardiac pump where the right and left hearts are 
described by the following time-varying elastance 
model [3]. 
 
Cardiac Dysfunction in Sepsis 
  
     Sepsis stimulates the release of multiple 
inflammatory mediators which induce important effects 
on vascular smooth muscles and compromise the 
cardiac function by causing myocardial depression. This 
results in a rise in the left ventricle compliance and a 
severely depressed ejection fraction [5]. However this is 
most commonly masked by an elevated cardiac output. 
Similar patterns have been observed in the right 
ventricle. 
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Where Ediast and Esyst represent the end-diastolic and 
end-systolic elastance values respectively, T is the 
cardiac cycle and Tsyst defines the systolic interval and is 
given by )1-t(T3.0≈)t(Tsyst . 
     The theoretical pressure-volume loops corresponding 
to normal and septic patients are plotted in Figure 5. 
Esyst represents the slope of the end systolic pressure 
volume relationship and is assimilated to the ventricle 
contractility.  In survivors of severe sepsis, an adequate 
stroke volume is maintained in the early stage by an 
increase in the end diastolic volume. In nonsurvivors, 
failure to increase the end diastolic compliance results 
in inability to maintain the same stroke volume [5]. 
These alterations in ventricular function and size are 
transients and return to normal in survivors after 7 to 10 
days in general. 
     The mathematical model of the baroreflex has been 
adapted from [4]. The model includes the afferent 
carotid baroreflex pathway, the sympathetic and the 
vagal efferent activities.  The effector sites of these 
nerve stimulations are the left and right ventricular 
maximum elastances, the heart period and the different 
peripheral arterial resistances. Figure 4 is depicts the 
structure of the baroreflex model.  
 
 
 
 
 
 
 
 
 
Baroreceptor 
Sympathetic 
Vagal 
     Elastance 
 
    Unstressed 
    Volume 
 
    Peripheral 
    Resistances 
 
     Heart rate 
Carotid Sinus 
Pressure 
 
 Esyst 
normal
Esyst    
severe spesis 
 
 
 
Pr
es
su
re
   
 
 
Afferent pathway            Efferent pathways             Effectors       
Figure 4: Baroreceptor firing pathways  
  
The drug transport model consists of the same number 
of compartments as the CVS and is used to calculate the 
drug concentrations in the relevant body compartments. 
Drug concentration in each compartment is calculated 
by applying the following mass balance equation : 
 
 
Volume   
Figure 5: Pressure-volume loops for a normal patient 
(solid line), survivors (dotted line) and non-survivors 
(dashed line) of severe sepsis  
τ M.ln2/-C.Q -C.Qdt/dM outoutinin=  (2)  
  
Where M is the mass of drug in the compartment, Cin 
and Cout represent the inflow and outflow 
concentrations, Qin and Qout are the inward (leaving the 
previous compartment) and outward blood flows 
respectively and τ is the drug half-life. The 
instantaneous drug concentration is calculated as 
follows 
Simulation Results 
 
    The parameters of the CVS model correspond to a 
human subject of 75 Kg with a total blood volume of 
5.6 litres and a heart rate of 75 bpm [2].  For integration 
the Euler method was used with a step size of 0.005 sec. 
Initial compartment volumes have been calculated for 
each compartment as the sum of the unstressed volume 
and the volume given by the integration procedure (i.e. 
the stressed volume). 
     Initial simulations results are presented for a healthy 
patient under normal conditions. The steady-states 
hemodynamic variables are shown in Figures 6-8. 
 
Figure 6: Left ventricle pressure, volume and flow 
 
Figure 7: Right ventricle pressure, volume and flow 
 
Figure 8: Hemodynamic parameters 
 
     Vascular dilation has been simulated as a 40% 
decrease in all systemic resistances. Myocardial 
depression in the early stage of sepsis was simulated as 
30% decrease in left and right ventricular systolic 
elastance. The results are shown in Figure 9-11. A 
decrease in the systemic vascular resistance (SVR) 
reduces the afterload which is relfected by a lower mean 
arterial pressure (MAP) as shown in Figure 10. The 
result is an elevated cardiac output despite a reduction 
in the ventricle contractilities.  
 
Figure 9: Left ventricle pressure, volume and flow in 
sepsis 
 
 
Figure 10: Right ventricle pressure, volume and flow in 
sepsis 
 
Figure 11: Hemodynamic parameters in sepsis 
 
     Both PV loops are plotted in Figure 12 for 
comparison. The PV loops for the left and right 
ventricles have moved to the right in the septic case 
owing to a decrease in the slope of the end systolic 
pressure volume relationship characteristic. The slight 
increase in the end diastolic volume is the result of 
biventricular dilation which accompanies the 
myocardial depression.  
 
 
 
 
Figure 14: Left ventricle PV loops for different doses of 
dobutamine 
Figure 12: Left ventricle PV loops for normal and septic 
patients 
 
     The baroreflex compensates for a decrease in the 
MAP by adjusting the parameters of the CVS model 
(Figure 4). On the other hand and according to the data 
used in this simulation study, dobutamine’s controlled 
parameters are the ventricle contractilities, the heart rate 
and the muscle arteriolar resistance.  
 
     Dobutamine is a potent inotrope. It works at a 
number of different receptor sites in the body, however 
it mostly acts on beta-receptors in the heart to increase 
the force of myocardial contraction with relatively 
minor chronotropic and vascular side effects.       The next simulation results are intended to illustrate 
the interaction of dobutamine with overall CVS model 
including baroreflex control. Dobutamine infusion rate 
has been set to 10 µg/kg/min with baroreflex control 
included. Figure 15 shows the response of the different 
hemodynamic variables. Baroreflex control first 
compensates for the changes induced in SVR and 
contractility in order to restore an adequate MAP as 
seen in the initial stage of the simulation. After drug 
infusion has been initiated, a second counteraction is 
exerted by the baroreflex in response to dobutamine 
effects on the circulatory parameters. 
     Baroreflex control has been removed in the 
subsequent simulations in order to emphasize the dose 
related effects of dobutamine on the contractility.  
     Dobutamine infusion is started at time 200 sec. and 
the onset of effect is delayed by 30 sec. The results of 
Figure 13 show a marked increase in the cardiac output 
as a results of the inotropic effects of dobutamine. There 
is a small decrease in SVR. For larger doses, there is a 
significant increase in heart rate and consequently a 
slight fall in stroke volume. 
 
 
 
Figure 13: Hemodynamic responses to different 
dobutamine doses 
 Figure 15: Hemodynamic responses with baroreceptor 
 
Figure 14 shows the left ventricle PV loops related to 
different dosage of dobutamine. The curves are shifted 
to the left as a result of an improved myocardial 
contractility. Usually, dobutamine is accompanied with 
a vasoconstrictor to improve the SVR and hence the 
afterload. One such vasoactive agent which is frequently 
used with dobutamine is noradrenaline. 
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Figure 17: Changes in the controlled CVS model 
resistances and unstressed volume  
 
Conclusions 
 
     In this paper the interaction of vasoactive drugs, such 
as dobutamine, with the cardiovascular system in 
patients with sepsis induced myocardial dysfunction has 
been modelled and analysed. The physiological model 
has successfully predicted how the cardiovascular 
hemodynamics are affected by different drug doses of 
dobutamine. The model can also be extended to 
simulate multiple drug therapy given the quantitative 
information about the direct actions of these drugs on 
the relevant cardiovascular parameters. It is hoped to 
conduct such a comprehensive study in the future. 
